Abstract
This study evaluates the efficacy of dose-adjusted CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy as a mobilization regimen for autologous peripheral blood stem cells (APBSCs) in patients with high-risk non-Hodgkin’s lymphoma (NHL). The results demonstrate that dose-adjusted CHOP effectively mobilizes stem cells and that the addition of rituximab significantly improves the complete response (CR) rate for B-cell lymphoma patients without compromising engraftment or increasing toxicity.
Introduction
For patients with high-risk NHL, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard therapeutic approach. A critical step in this process is the mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood for collection. While various chemotherapy-based mobilization strategies exist, the impact of adding rituximab—a potent anti-CD20 monoclonal antibody—on stem cell yield and subsequent engraftment has been a subject of clinical debate. This retrospective study investigates whether dose-adjusted CHOP, with or without rituximab, serves as an effective and safe mobilization tool.
Methodology
The researchers analyzed 39 patients with high-risk NHL eligible for ASCT. Patients received either dose-adjusted CHOP (n=25) or R-CHOP (n=14). Following chemotherapy, recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered to stimulate stem cell release. Successful mobilization was defined as a minimum collection of $2.0 \times 10^6$ CD34+ cells/kg of body weight.
Predictive Factors for Stem Cell Yield
The study identified key clinical indicators that correlate with successful stem cell harvest. Multivariable analysis revealed that younger patient age and a higher percentage of CD34+ cells in the peripheral blood on the first day of collection were significant predictors of a higher total CD34+ cell yield.
Key Findings and Clinical Outcomes
While the addition of rituximab resulted in a lower median yield of CD34+ cells ($5.01 \times 10^6$ cells/kg vs. $8.25 \times 10^6$ cells/kg in the CHOP-only group), the overall mobilization success rate remained high at 94.5%. Importantly, the R-CHOP group showed a superior clinical response, achieving a 100% CR rate in B-cell lymphoma patients compared to 50% in the CHOP group ($P = 0.01$).
Long-term follow-up showed encouraging survival rates across the entire cohort, with a 5-year progression-free survival (PFS) of 65.7% and an overall survival (OS) of 75.6%.
Conclusion
Dose-adjusted CHOP is a robust mobilization regimen for high-risk NHL. The integration of rituximab enhances oncological outcomes for B-cell lymphoma patients without hindering the feasibility of stem cell collection or the success of subsequent transplantation. Although limited by its retrospective nature and small sample size, this study supports the use of R-CHOP as a safe and effective mobilization strategy.
Summary updated